{"id":3304,"date":"2012-04-05T02:49:29","date_gmt":"2012-04-05T02:49:29","guid":{"rendered":"https:\/\/boselli.com.br\/?p=3304"},"modified":"2025-01-22T10:49:54","modified_gmt":"2025-01-22T13:49:54","slug":"decreto-n%c2%ba-7-713-de-3-de-abril-de-2012","status":"publish","type":"post","link":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/","title":{"rendered":"Decreto n\u00ba 7.713, de 3 de abril de 2012"},"content":{"rendered":"

Decreto n\u00ba 7.713, de 3 de abril de 2012<\/strong><\/p>\n

Estabelece a aplica\u00e7\u00e3o de margem de prefer\u00eancia nas licita\u00e7\u00f5es realizadas no \u00e2mbito da Administra\u00e7\u00e3o P\u00fablica Federal para aquisi\u00e7\u00e3o de f\u00e1rmacos e medicamentos descritos no Anexo I, para fins do disposto no art. 3o<\/sup> da Lei no<\/sup> 8.666, de 21 de junho de 1993.<\/p>\n

A PRESIDENTA DA REP\u00daBLICA<\/strong>, no uso das atribui\u00e7\u00f5es que lhe confere o art. 84,\u00a0caput, inciso IV, da Constitui\u00e7\u00e3o, e tendo em vista o disposto no art. 3o<\/sup>, \u00a7\u00a7 5o<\/sup>, 6o<\/sup>, 8o<\/sup> e 9o<\/sup>, da Lei no<\/sup>8.666, de 21 de junho de 1993,<\/p>\n

DECRETA<\/strong>:<\/p>\n

Art.\u00a01o<\/sup> Fica estabelecida a aplica\u00e7\u00e3o de margem de prefer\u00eancia para aquisi\u00e7\u00e3o de f\u00e1rmacos e medicamentos, conforme percentuais e descri\u00e7\u00f5es do Anexo I, nas licita\u00e7\u00f5es realizadas no \u00e2mbito da administra\u00e7\u00e3o p\u00fablica federal, com vistas \u00e0 promo\u00e7\u00e3o do desenvolvimento nacional sustent\u00e1vel.<\/p>\n

Par\u00e1grafo\u00a0\u00fanico.\u00a0\u00a0Os editais para aquisi\u00e7\u00e3o dos produtos descritos no Anexo I, publicados ap\u00f3s a data de entrada em vigor deste Decreto, dever\u00e3o contemplar a aplica\u00e7\u00e3o da margem de prefer\u00eancia de que trata o\u00a0caput.<\/p>\n

Art.\u00a02o<\/sup> Ser\u00e1 aplicada a margem de prefer\u00eancia de que trata o art. 1o<\/sup> apenas para os produtos manufaturados nacionais, conforme as regras de origem estabelecidas em portaria do Ministro de Estado do Desenvolvimento, Ind\u00fastria e Com\u00e9rcio Exterior.<\/p>\n

\u00a7\u00a01o<\/sup> O licitante dever\u00e1 apresentar, juntamente com a proposta, formul\u00e1rio de declara\u00e7\u00e3o de cumprimento das regras de origem, conforme modelo publicado em portaria do Ministro de Estado do Desenvolvimento, Ind\u00fastria e Com\u00e9rcio Exterior.<\/p>\n

\u00a7 2o<\/sup> Na modalidade preg\u00e3o eletr\u00f4nico:<\/p>\n

I\u00a0–\u00a0o licitante declarar\u00e1, durante a fase de cadastramento das propostas, se o produto atende \u00e0s regras de origem; e<\/p>\n

II\u00a0–\u00a0o formul\u00e1rio referido no \u00a7 1o<\/sup> dever\u00e1 ser apresentado com os documentos exigidos para habilita\u00e7\u00e3o.<\/p>\n

\u00a7\u00a03o<\/sup> O produto que n\u00e3o atender \u00e0s regras de origem ou cujo licitante n\u00e3o apresentar tempestivamente o formul\u00e1rio referido neste artigo ser\u00e1 considerado como produto manufaturado estrangeiro para fins deste Decreto.<\/p>\n

Art.\u00a03o<\/sup> A margem de prefer\u00eancia de que trata o art. 1o<\/sup> ser\u00e1 calculada sobre o menor pre\u00e7o ofertado de produto manufaturado estrangeiro, conforme a f\u00f3rmula prevista no Anexo II e as seguintes condi\u00e7\u00f5es:<\/p>\n

I\u00a0–\u00a0o pre\u00e7o ofertado de produto manufaturado nacional ser\u00e1 considerado menor que PE, sempre que seu valor for igual ou inferior a PM; e<\/p>\n

II\u00a0–\u00a0o pre\u00e7o ofertado de produto manufaturado nacional ser\u00e1 considerado maior que PE, sempre que seu valor for superior a PM.<\/p>\n

Art.\u00a04o<\/sup> A margem de prefer\u00eancia de que trata o art. 1o<\/sup> ser\u00e1 aplicada para classifica\u00e7\u00e3o das propostas:<\/p>\n

I\u00a0–\u00a0ap\u00f3s a fase de lances, na modalidade de preg\u00e3o; e<\/p>\n

II\u00a0–\u00a0no julgamento e classifica\u00e7\u00e3o das propostas, nas demais modalidades de licita\u00e7\u00e3o.<\/p>\n

\u00a7\u00a01o<\/sup> A margem de prefer\u00eancia prevista n\u00e3o ser\u00e1 aplicada caso o pre\u00e7o mais baixo ofertado seja do produto manufaturado nacional.<\/p>\n

\u00a7\u00a02o<\/sup> Caso o licitante da proposta classificada em primeiro lugar seja inabilitado, ou deixe de cumprir a obriga\u00e7\u00e3o prevista no inciso II do \u00a7 2o<\/sup> do art. 2o<\/sup>, dever\u00e1 ser realizada a reclassifica\u00e7\u00e3o das propostas, para fins de aplica\u00e7\u00e3o da margem de prefer\u00eancia.<\/p>\n

\u00a7\u00a03o<\/sup> Caso a licita\u00e7\u00e3o tenha por crit\u00e9rio de julgamento o menor pre\u00e7o do grupo ou lote, a margem de prefer\u00eancia s\u00f3 ser\u00e1 aplicada se todos os itens que comp\u00f5em o grupo ou lote atenderem \u00e0s regras de origem de que trata o art. 2o<\/sup>.<\/p>\n

\u00a7\u00a04o<\/sup> A aplica\u00e7\u00e3o da margem de prefer\u00eancia n\u00e3o exclui a negocia\u00e7\u00e3o entre o pregoeiro e o vencedor da fase de lances, prevista no\u00a0\u00a7 8o<\/sup> do art. 24 do Decreto no<\/sup> 5.450, de 31 de maio de 2005<\/a>.<\/p>\n

\u00a7\u00a05o<\/sup> A aplica\u00e7\u00e3o da margem de prefer\u00eancia n\u00e3o exclui o direito de prefer\u00eancia das microempresas e empresas de pequeno porte, previsto nos\u00a0arts. 44<\/a> e\u00a045 da Lei Complementar no<\/sup> 123, de 14 de dezembro de 2006<\/a>.<\/p>\n

\u00a7\u00a06o<\/sup> A aplica\u00e7\u00e3o da margem de prefer\u00eancia estar\u00e1 condicionada ao cumprimento, no momento da licita\u00e7\u00e3o, do disposto no\u00a0\u00a7 9o<\/sup> do art. 3o<\/sup> da Lei no<\/sup> 8.666, de 21 de junho de 1993<\/a>.<\/p>\n

Art.\u00a05o<\/sup> Os estudos previstos no\u00a0\u00a7 6o<\/sup> do art. 3o<\/sup> da Lei no<\/sup> 8.666, de 1993<\/a>, ser\u00e3o revistos anualmente a partir da data de publica\u00e7\u00e3o deste Decreto.<\/p>\n

Art.\u00a06o<\/sup> As margens de prefer\u00eancia de que trata o art. 1o<\/sup> ser\u00e3o aplicadas at\u00e9 30 de mar\u00e7o de 2014, no caso dos produtos do Grupo 1, e at\u00e9 30 de mar\u00e7o de 2017, no caso dos produtos dos Grupos 2, 3, 4, 5 e 6, conforme descrito no Anexo I.<\/p>\n

Art. 7o<\/sup> Este Decreto entra em vigor na data da sua publica\u00e7\u00e3o.<\/p>\n

Bras\u00edlia, 3 de abril\u00a0 de 2012; 191o<\/sup> da Independ\u00eancia e 124o<\/sup> da Rep\u00fablica.<\/p>\n

DILMA ROUSSEFF
\nGuido Mantega<\/p>\n

Este texto n\u00e3o substitui o publicado no DOU de 4.4.2012<\/p>\n

ANEXO I<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Produto<\/td>\nC\u00f3digo TIPI<\/td>\nMargem de Prefer\u00eancia Normal<\/td>\nMargem de Prefer\u00eancia Adicional<\/td>\n<\/tr>\n
Grupo 1 – Medicamentos nacionais que utilizem em sua formula\u00e7\u00e3o f\u00e1rmacos importados<\/td>\n<\/tr>\n
Atazanavir<\/td>\n3004.90.68<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Ganciclovir<\/td>\n3004.90.69<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Gosserelina<\/td>\n3004.39.27<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Hidroxiur\u00e9ia<\/td>\n3004.90.99<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Indinavir Sulfato<\/td>\n3004.90.68<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Insulina<\/td>\n3004.31.00<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Isoniazida\/Rifampicina\/Pirazinamida\/Etambutol<\/td>\n3004.90.99<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Levotiroxina<\/td>\n3004.39.81<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Mitoxantrona<\/td>\n3004.90.39<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Talidomida<\/td>\n3004.90.42<\/td>\n8%<\/td>\n–<\/td>\n<\/tr>\n
Grupo 2 – Medicamentos nacionais que utilizem em sua formula\u00e7\u00e3o f\u00e1rmacos nacionais<\/td>\n<\/tr>\n
Amoxicilina<\/td>\n3004.10.12<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Benzonidazol<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Captopril<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Carbamazepina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Cefalexina<\/td>\n3004.20.52<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Cefalotina S\u00f3dica<\/td>\n3004.20.51<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Cetoconazol<\/td>\n3004.90.77<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Clozapina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Diazepan<\/td>\n3004.90.64<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Didanosina (DDI)<\/td>\n3004.90.79<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Dietilcarbamazina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Efavirenz<\/td>\n3004.90.78<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Estavudina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Produto<\/td>\nC\u00f3digo TIPI<\/td>\nMargem de Prefer\u00eancia<\/td>\nMargem de Prefer\u00eancia Adicional<\/td>\n<\/tr>\n
Fenitoina S\u00f3dico<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Fenobarbital S\u00f3dico<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Haloperidol<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Imatinibe Mesilato<\/td>\n3004.90.68<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Lamivudina<\/td>\n3004.90.79<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Nevirapina<\/td>\n3004.90.68<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Octreotida<\/td>\n3004.39.26<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Olanzapina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Propanolol Cloridrato<\/td>\n3004.90.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Quetiapina Sulfato<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Ritonavir<\/td>\n3004.90.78<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Rivastigmina<\/td>\n3004.90.69<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Saquinavir<\/td>\n3004.90.68<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sevelamer<\/td>\n3004.90.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sirolimo<\/td>\n3004.90.78<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sulfametoxazol<\/td>\n3004.90.72<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sulfato heptaidratado de Fe<\/td>\n3004.90.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Tacrolimo<\/td>\n3004.90.78<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Tenofovir<\/td>\n3004.90.68<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Trimetoprima<\/td>\n3004.90.61<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Zidovudina (AZT)<\/td>\n3004.90.79<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Grupo 3 – F\u00e1rmacos nacionais<\/td>\n<\/tr>\n
Amoxicilina<\/td>\n2941.10.20<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Benzonidazol<\/td>\n2933.29.19<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Captopril<\/td>\n2933.99.49<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Carbamazepina<\/td>\n2933.99.32<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Cefalexina<\/td>\n2941.90.33<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Produto<\/td>\nC\u00f3digo TIPI<\/td>\nMargem de Prefer\u00eancia<\/td>\nMargem de Prefer\u00eancia Adicional<\/td>\n<\/tr>\n
Cefalotina S\u00f3dica<\/td>\n2941.90.33<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Cetoconazol<\/td>\n2934.99.31<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Clozapina<\/td>\n2933.99.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Diazepan<\/td>\n2933.91.22<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Didanosina (DDI)<\/td>\n2934.99.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Dietilcarbamazina<\/td>\n2933.59.04<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Efavirenz<\/td>\n2933.39.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Estavudina<\/td>\n2934.99.27<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Fenitoina S\u00f3dico<\/td>\n2933.21.21<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Fenobarbital S\u00f3dico<\/td>\n2933.53.40<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Haloperidol<\/td>\n2933.39.15<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Imatinibe Mesilato<\/td>\n2933.59.19<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Lamivudina<\/td>\n2934.99.93<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Nevirapina<\/td>\n2934.99.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Octreotida<\/td>\n2937.19.90<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Olanzapina<\/td>\n2933.99.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Propanolol Cloridrato<\/td>\n2922.50.50<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Quetiapina Sulfato<\/td>\n2933.99.39<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Ritonavir<\/td>\n2934.99.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Rivastigmina<\/td>\n2933.49.90<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Saquinavir<\/td>\n2934.99.10<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sevelamer<\/td>\n2922.50.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sirolimo<\/td>\n2934.99.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sulfametoxazol<\/td>\n2935.00.25<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Sulfato heptaidratado de Fe<\/td>\n2833.29.90<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Tacrolimo<\/td>\n2934.99.99<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Tenofovir<\/td>\n2933.59.49<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Trimetoprima<\/td>\n2933.59.41<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Produto<\/td>\nC\u00f3digo TIPI<\/td>\nMargem de Prefer\u00eancia Normal<\/td>\nMargem de Prefer\u00eancia Adicional<\/td>\n<\/tr>\n
Zidovudina (AZT)<\/td>\n2934.99.22<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Grupo 4 \u2013 Insumos farmac\u00eauticos n\u00e3o ativos (adjuvantes) nacionais<\/td>\n<\/tr>\n
C\u00e1psulas Gelatinosas<\/td>\n9602.00.10<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Celulose Microcristalina<\/td>\n3912.90.31<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Croscarmelose S\u00f3dica<\/td>\n3912.31.19<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Glicolato de Amido S\u00f3dico<\/td>\n3505.10.00<\/td>\n20%<\/td>\n–<\/td>\n<\/tr>\n
Grupo 5 \u2013 Medicamentos nacionais que utilizem em sua formula\u00e7\u00e3o biof\u00e1rmacos com produ\u00e7\u00e3o tecnol\u00f3gica integrada no pa\u00eds<\/td>\n<\/tr>\n
3002.10.39<\/td>\nAdalimumabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3004.90.19<\/td>\nAlfadornase<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nAlfaepoetina<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.36<\/td>\nAlfainterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.36<\/td>\nAlfapeginterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.36<\/td>\nBetainterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.38<\/td>\nEtanercepte<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nFilgrastima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3004.39.12<\/td>\nGonadotrofina Cori\u00f4nica<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nHeparina S\u00f3dica<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nImiglucerases (Imiglucerase, Taliglucerase, Veloglucerase, outras)<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nImunoglobulina Anti Hepatite B<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nImunoglobulina Humana<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nInfliximabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nLenograstima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nMolgramostima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nNatalizumabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3004.90.19<\/td>\nPancreatina<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.39<\/td>\nPancrelipase<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.38<\/td>\nRituximabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3004.39.11<\/td>\nSomatropina<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.90.92<\/td>\nToxina Botulinica<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
Grupo 6 \u2013 Biof\u00e1rmacos com produ\u00e7\u00e3o tecnol\u00f3gica integrada no pa\u00eds<\/td>\n<\/tr>\n
3002.10.29<\/td>\nAdalimumabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3507.90.49<\/td>\nAlfadornase<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nAlfaepoetina<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nAlfainterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nAlfapeginterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nbetainterferona<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nEtanercepte<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3001.20.90<\/td>\nFilgrastima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3001.90.90<\/td>\nGonadotrofina Cori\u00f4nica<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3001.90.10<\/td>\nHeparina S\u00f3dica<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nImiglucerases(Imiglucerase, Taliglucerase, Veloglucerase, outras)<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.23<\/td>\nImunoglobulina Anti Hepatite B<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.23<\/td>\nImunoglobulina Humana<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nInfliximabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nLenograstima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nMolgramostima<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nNatalizumabe<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3507.90.19<\/td>\nPancreatina<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3001.20.90<\/td>\nPancrelipase<\/td>\n20%<\/td>\n5%<\/td>\n<\/tr>\n
3002.10.29<\/td>\nRituximabe<\/span><\/td>\n20%<\/span><\/td>\n5%<\/span><\/td>\n<\/tr>\n
2937.11.00<\/span><\/td>\nSomatropina<\/span><\/td>\n20%<\/span><\/td>\n5%<\/span><\/td>\n<\/tr>\n
3002.90.90<\/span><\/td>\nToxina Botulinica<\/span><\/td>\n20%<\/span><\/td>\n5%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ANEXO II<\/strong><\/span><\/p>\n

F\u00f3rmula<\/span><\/p>\n

PM = PE x (1 + M), sendo:<\/span><\/p>\n

PM – pre\u00e7o com margem;<\/span><\/p>\n

PE – menor pre\u00e7o ofertado do produto manufaturado estrangeiro;<\/span><\/p>\n

M – margem de prefer\u00eancia em percentagem, conforme estabelecido no Anexo I a este Decreto.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Decreto n\u00ba 7.713, de 3 de abril de 2012 Estabelece a aplica\u00e7\u00e3o de margem de prefer\u00eancia nas licita\u00e7\u00f5es realizadas no \u00e2mbito da Administra\u00e7\u00e3o P\u00fablica Federal para aquisi\u00e7\u00e3o de f\u00e1rmacos e medicamentos descritos no Anexo I, para fins do disposto no art. 3o da Lei no 8.666, de 21 de junho de 1993. A PRESIDENTA DA […]<\/p>\n","protected":false},"author":5,"featured_media":32871,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-3304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-leis-tabeladas"],"yoast_head":"\nDecreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/boselli.com.br\/site\/decreto-n\u00ba-7-713-de-3-de-abril-de-2012\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es\" \/>\n<meta property=\"og:description\" content=\"Decreto n\u00ba 7.713, de 3 de abril de 2012 Estabelece a aplica\u00e7\u00e3o de margem de prefer\u00eancia nas licita\u00e7\u00f5es realizadas no \u00e2mbito da Administra\u00e7\u00e3o P\u00fablica Federal para aquisi\u00e7\u00e3o de f\u00e1rmacos e medicamentos descritos no Anexo I, para fins do disposto no art. 3o da Lei no 8.666, de 21 de junho de 1993. A PRESIDENTA DA […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/boselli.com.br\/site\/decreto-n\u00ba-7-713-de-3-de-abril-de-2012\/\" \/>\n<meta property=\"og:site_name\" content=\"Boselli Licita\u00e7\u00f5es\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-05T02:49:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-22T13:49:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1350\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paulo Boselli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paulo Boselli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/\"},\"author\":{\"name\":\"Paulo Boselli\",\"@id\":\"https:\/\/boselli.com.br\/site\/#\/schema\/person\/4dcd2c90156c9b28e990848ee2112775\"},\"headline\":\"Decreto n\u00ba 7.713, de 3 de abril de 2012\",\"datePublished\":\"2012-04-05T02:49:29+00:00\",\"dateModified\":\"2025-01-22T13:49:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/\"},\"wordCount\":1267,\"publisher\":{\"@id\":\"https:\/\/boselli.com.br\/site\/#organization\"},\"image\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg\",\"articleSection\":[\"Leis\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/\",\"url\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/\",\"name\":\"Decreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es\",\"isPartOf\":{\"@id\":\"https:\/\/boselli.com.br\/site\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg\",\"datePublished\":\"2012-04-05T02:49:29+00:00\",\"dateModified\":\"2025-01-22T13:49:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage\",\"url\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg\",\"contentUrl\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg\",\"width\":1350,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/boselli.com.br\/site\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Decreto n\u00ba 7.713, de 3 de abril de 2012\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/boselli.com.br\/site\/#website\",\"url\":\"https:\/\/boselli.com.br\/site\/\",\"name\":\"Boselli Licita\u00e7\u00f5es\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/boselli.com.br\/site\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/boselli.com.br\/site\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/boselli.com.br\/site\/#organization\",\"name\":\"Boselli Consultoria\",\"url\":\"https:\/\/boselli.com.br\/site\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/boselli.com.br\/site\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/cropped-boselli-licitacoes-so-marca-100.png\",\"contentUrl\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/cropped-boselli-licitacoes-so-marca-100.png\",\"width\":295,\"height\":100,\"caption\":\"Boselli Consultoria\"},\"image\":{\"@id\":\"https:\/\/boselli.com.br\/site\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/boselli.com.br\/site\/#\/schema\/person\/4dcd2c90156c9b28e990848ee2112775\",\"name\":\"Paulo Boselli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/boselli.com.br\/site\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/paulo-boselli-advogado-licitacao.png-150x150.jpg\",\"contentUrl\":\"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/paulo-boselli-advogado-licitacao.png-150x150.jpg\",\"caption\":\"Paulo Boselli\"},\"url\":\"https:\/\/boselli.com.br\/site\/author\/boselli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/boselli.com.br\/site\/decreto-n\u00ba-7-713-de-3-de-abril-de-2012\/","og_locale":"pt_BR","og_type":"article","og_title":"Decreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es","og_description":"Decreto n\u00ba 7.713, de 3 de abril de 2012 Estabelece a aplica\u00e7\u00e3o de margem de prefer\u00eancia nas licita\u00e7\u00f5es realizadas no \u00e2mbito da Administra\u00e7\u00e3o P\u00fablica Federal para aquisi\u00e7\u00e3o de f\u00e1rmacos e medicamentos descritos no Anexo I, para fins do disposto no art. 3o da Lei no 8.666, de 21 de junho de 1993. A PRESIDENTA DA […]","og_url":"https:\/\/boselli.com.br\/site\/decreto-n\u00ba-7-713-de-3-de-abril-de-2012\/","og_site_name":"Boselli Licita\u00e7\u00f5es","article_published_time":"2012-04-05T02:49:29+00:00","article_modified_time":"2025-01-22T13:49:54+00:00","og_image":[{"width":1350,"height":900,"url":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg","type":"image\/jpeg"}],"author":"Paulo Boselli","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paulo Boselli","Est. tempo de leitura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#article","isPartOf":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/"},"author":{"name":"Paulo Boselli","@id":"https:\/\/boselli.com.br\/site\/#\/schema\/person\/4dcd2c90156c9b28e990848ee2112775"},"headline":"Decreto n\u00ba 7.713, de 3 de abril de 2012","datePublished":"2012-04-05T02:49:29+00:00","dateModified":"2025-01-22T13:49:54+00:00","mainEntityOfPage":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/"},"wordCount":1267,"publisher":{"@id":"https:\/\/boselli.com.br\/site\/#organization"},"image":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage"},"thumbnailUrl":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg","articleSection":["Leis"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/","url":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/","name":"Decreto n\u00ba 7.713, de 3 de abril de 2012 - Boselli Licita\u00e7\u00f5es","isPartOf":{"@id":"https:\/\/boselli.com.br\/site\/#website"},"primaryImageOfPage":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage"},"image":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage"},"thumbnailUrl":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg","datePublished":"2012-04-05T02:49:29+00:00","dateModified":"2025-01-22T13:49:54+00:00","breadcrumb":{"@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#primaryimage","url":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg","contentUrl":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/boselli-consultoria-licitacao-destacada-geral.jpg","width":1350,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/boselli.com.br\/site\/decreto-n%c2%ba-7-713-de-3-de-abril-de-2012\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/boselli.com.br\/site\/"},{"@type":"ListItem","position":2,"name":"Decreto n\u00ba 7.713, de 3 de abril de 2012"}]},{"@type":"WebSite","@id":"https:\/\/boselli.com.br\/site\/#website","url":"https:\/\/boselli.com.br\/site\/","name":"Boselli Licita\u00e7\u00f5es","description":"","publisher":{"@id":"https:\/\/boselli.com.br\/site\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/boselli.com.br\/site\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/boselli.com.br\/site\/#organization","name":"Boselli Consultoria","url":"https:\/\/boselli.com.br\/site\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/boselli.com.br\/site\/#\/schema\/logo\/image\/","url":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/cropped-boselli-licitacoes-so-marca-100.png","contentUrl":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/cropped-boselli-licitacoes-so-marca-100.png","width":295,"height":100,"caption":"Boselli Consultoria"},"image":{"@id":"https:\/\/boselli.com.br\/site\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/boselli.com.br\/site\/#\/schema\/person\/4dcd2c90156c9b28e990848ee2112775","name":"Paulo Boselli","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/boselli.com.br\/site\/#\/schema\/person\/image\/","url":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/paulo-boselli-advogado-licitacao.png-150x150.jpg","contentUrl":"https:\/\/boselli.com.br\/site\/wp-content\/uploads\/2025\/01\/paulo-boselli-advogado-licitacao.png-150x150.jpg","caption":"Paulo Boselli"},"url":"https:\/\/boselli.com.br\/site\/author\/boselli\/"}]}},"_links":{"self":[{"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/posts\/3304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/comments?post=3304"}],"version-history":[{"count":1,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/posts\/3304\/revisions"}],"predecessor-version":[{"id":30451,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/posts\/3304\/revisions\/30451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/media\/32871"}],"wp:attachment":[{"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/media?parent=3304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/categories?post=3304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boselli.com.br\/site\/wp-json\/wp\/v2\/tags?post=3304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}